German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

Bayer CEO Bill Anderson says "everyone hates" the budget process and the bureaucracy involved. So he implemented 90-day ...

Bayer said its Elinzanetant drug, which targets some symptoms produced by endocrine therapy in women with breast cancer, met all primary and secondary endpoints in a study. The German pharmaceutical ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

The German pharmaceutical company has tied ... its Pharmacovigilance Artificial Intelligence (PVAI) products. These will be added to Bayer's existing pharmacovigilance database and IT systems ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

Bayer BAYN0.33%increase; green up pointing triangle said its eye treatment aflibercept at high doses showed positive results in a late-stage trial, including improved vision gains for people ...

Global Head of Research and Early Development for Oncology at Bayer’s Pharmaceuticals Division. “This innovative approach has the potential to enhance the treatment options available for patients, ...

Larotrectinib sulfate is under clinical development by Bayer and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition ...